A5086701098- Advanced Proteomics Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Metabolomics and Mass Spectrometry Studies
- Cancer, Lipids, and Metabolism
- Pancreatic function and diabetes
- Lung Cancer Treatments and Mutations
- Renal Transplantation Outcomes and Treatments
- Renal and related cancers
- Genetic and Kidney Cyst Diseases
- Mass Spectrometry Techniques and Applications
- Brain Metastases and Treatment
- Glycosylation and Glycoproteins Research
- Biosensors and Analytical Detection
- Epigenetics and DNA Methylation
- Chronic Kidney Disease and Diabetes
- Organ Transplantation Techniques and Outcomes
- Acute Kidney Injury Research
- Proteoglycans and glycosaminoglycans research
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Renal and Vascular Pathologies
- Inflammatory Biomarkers in Disease Prognosis
Max Planck Institute for Molecular Genetics
2021
Mosaiques Diagnostics and Therapeutics (Germany)
2017-2019
RWTH Aachen University
2018
Up to 40% of advance lung, melanoma and breast cancer patients suffer from brain metastases (BM) with increasing incidence. Here, we assessed whether circulating tumor cells (CTCs) in peripheral blood can serve as a disease surrogate, focusing on CD44 CD74 expression prognostic markers for BM. We show that size-based microfluidic approach combination semi-automated cell recognition system are well suited CTC detection BM allow further characterization potentially derived CTCs were found 50%...
Abstract Urinary profiling datasets, previously acquired by capillary electrophoresis coupled to mass-spectrometry were investigated identify a general urinary marker pattern for detection of solid tumors targeting common systemic events associated with tumor-related inflammation. A total 2,055 profiles analyzed, derived from a) cancer group patients (n = 969) bladder, prostate, and pancreatic cancers, renal cell carcinoma, cholangiocarcinoma b) control benign diseases 556), inflammatory...
Abstract Renal Cysts and Diabetes Syndrome (RCAD) is an autosomal dominant disorder caused by mutations in the HNF1B gene encoding for transcriptional factor hepatocyte nuclear factor-1B. RCAD characterized as a multi-organ disease, with broad spectrum of symptoms including kidney abnormalities (renal cysts, renal hypodysplasia, single kidney, horseshoe kidneys, hydronephrosis), early-onset diabetes mellitus, abnormal liver function, pancreatic hypoplasia genital tract malformations. In...
Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed guide clinical intervention. As a follow-up previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded investigation towards with longitudinal data. Profiling datasets information regarding status were investigated. The peptidomics dataset (n = 98) was split into training test set. Cox regression utilized feature selection...
Purpose Urine is a rich source of potential biomarkers, including glycoproteins. Glycoproteomic analysis remains difficult due to the high heterogeneity glycans. Nevertheless, recent advances in glycoproteomics software solutions facilitate glycopeptide identification and characterization. The aim investigate intact glycopeptides urinary peptide profiles normal subjects using novel PTM‐centric software—Byonic. Experimental design 238 subjects, previously analyzed CE–MS CE–MS/MS and/or...
Introduction: Biomarkers are expected to improve the management of cancer patients by enabling early detection and prediction therapeutic response. Proteins reflect a molecular phenotype, have high potential as biomarkers, also key targets for intervention. Given ease collection proximity certain tumors, urinary proteome is rich source biomarkers several proteins been already implemented. Areas covered: We examined literature on urine analysis in oncology from reports published during last 5...